Indeed, Once China approves the CVD indication for Vascepa that will be a massive opportunity for Edding. For any potential BP acquirer the question may be if there are strategies a BP could employ to help Edding optimize (and hold) that market. The exclusivity protection (as is for Europe out to 2039) does not exist in China. Edding not only needs to make Vascepa a winner but must protect their market once it is established. That may be a critical factor for any potential BP acquirer of AMRN as revenues in China could be of blockbuster proportions. Protecting against competition will be critical.